Compare · KPRX vs NVO
KPRX vs NVO
Side-by-side comparison of Kiora Pharmaceuticals Inc. (KPRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KPRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 16017.8x KPRX ($11.4M).
- Over the past year, KPRX is down 19.6% and NVO is down 45.7% - KPRX leads by 26.1 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for KPRX).
- NVO has more recent analyst coverage (25 ratings vs 1 for KPRX).
- Company
- Kiora Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $2.56-3.75%
- $41.01-4.51%
- Market cap
- $11.4M
- $183.15B
- 1M return
- +4.91%
- -10.44%
- 1Y return
- -19.59%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 8
- Recent ratings
- 1
- 25
Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is based in Salt Lake City, Utah.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KPRX
- SEC Form 424B3 filed by Kiora Pharmaceuticals Inc.
- SEC Form EFFECT filed by Kiora Pharmaceuticals Inc.
- SEC Form S-3 filed by Kiora Pharmaceuticals Inc.
- Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Kiora Pharmaceuticals Inc.
- SEC Form DEF 14A filed by Kiora Pharmaceuticals Inc.
- SEC Form D filed by Kiora Pharmaceuticals Inc.
- Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Tosca Melissa
- SEC Form 4 filed by Daniels Eric Joseph
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care